Abstract
Calcineurin inhibitors (CNIs) have been the foundation of immunosuppression in solid organ transplantation since the 1980s. Cyclosporine A (CSA), the first in class, was identified as the metabolite of the soil fungus Tolypocladium inflatum Gams as part of a larger program of screening for naturally occurring fungal metabolites with biologic activity in the 1970s. Significant immunosuppressive effects were discovered and consequently CSA was trialed as an immunosuppressant in renal transplantation. This initial success led to its widespread study and adoption in solid organ transplantation. This novel agent yielded significant improvements in both 1 year and longer-term allograft and patient survival. Subsequently, a similar and more potent CNI, tacrolimus was developed. Today, it is the principal CNI used for prevention of allograft rejection. Like all other immunosuppressives, the benefits of CNIs are counterbalanced by side effects and complications resulting from drug toxicity. This chapter comprehensively reviews the clinical use of CNIs in cardiac transplantation.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ahuja SS, Shrivastav S, Danielpour D, Balow JE, Boumpas DT (1995) Regulation of transforming growth-factor b1 and its receptor by cyclosporine in human T lymphocytes. Transplantation 60:718–723
Anghel D, Tanasescu R, Campeanu A, Lupescu I, Podda G, Bajenaru O (2013) Neurotoxicity of immunosuppressive therapies in organ transplantation. Maedica (Bucur) 8(2):170–175
Arnold R, Pussell BA, Pianta TJ, Lin CS, Kiernan MC, Krishnan AV (2013) Association between calcineurin inhibitor treatment and peripheral nerve dysfunction in renal transplant recipients. Am J Transplant 13(9):2426–2432
Borel JF, Feurer C, Gubler HU, Stähelin H (1994) Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions 43:179–186
Brigham MD, Milgroom A, Lenco MO, Wang Z, Kent JD, LaMoreaux B, Johnson RJ, Mandell BF, Hadker N, Sanchez H, Francis K, Radeck LP, Miyasato G, Li JW (2020) Immunosuppressant use and gout in the prevalent solid organ transplantation population. Prog Transplant 30(2):103–110
Cantarovich M, Giannetti N, Barkun J, Cecere R (2004) Antithymocyte globulin induction allows a prolonged delay in the initiation of cyclosporine in heart transplant patients with postoperative renal dysfunction. Transplantation 78:779
Chakkera HA, Mandarino LJ (2013) Calcineurin inhibition and new-onset diabetes mellitus after transplantation. Transplantation 95(5):647–652
Cheng M (2013) Hartmann Stahelin (1925-2011) and the contested history of cyclosporin A. Clin Transpl 27:326–329
Cheung A, Menkis AH (1998) Cyclosporine heart transplantation. Transplant Proc 30(5):1881–1884
Christians U, Schmitz V, Haschke M (2005) Functional interactions between P-glycoprotein and CYP3A in drug metabolism. Expert Opin Drug Metab Toxicol 1(4):641–654
Clerk A, Harrison JG, Long CS, Sugden PH (1999) Pro-inflammatory cytokines stimulate mitogen-activated protein kinase subfamilies, increase phosphorylation of c-Jun and ATF2 and upregulate c-Jun protein in neonatal rat ventricular myocytes. J Mol Cell Cardiol 31(12):2087–2099
Coe CL, Horst SN, Izzy MJ (2020) Neurologic toxicities associated with tumor necrosis factor inhibitors and calcineurin inhibitors. Neurol Clin 38(4):937–951
Costanzo MR, Dipchand A, Starling R et al (2010) The International Society of Heart and Lung Transplantation guidelines for the care of heart transplant recipients. J Heart Lung Transplant 29:914
Das L, Levine AD (2008) TGF-beta inhibits IL-2 production and promotes cell cycle arrest in TCR-activated effector/memory T cells in the presence of sustained TCR signal transduction. J Immunol 180(3):1490–1498
Dongari A, McDonnell HT, Langlais RP (1993) Drug-induced gingival overgrowth. Oral Surg Oral Med Oral Pathol 76:543
Dumont FJ, Staruch MJ, Koprak SL, Siekierka JJ, Lin CS, Harrison R, Sewell T, Kindt VM, Beattie TR, Wyvratt M et al (1992) The immunosuppressive and toxic effects of FK-506 are mechanistically related: pharmacology of a novel antagonist of FK-506 and rapamycin. J Exp Med 176(3):751–760
Ekberg H, Bernasconi C, Tedesco-Silva H, Vítko S, Hugo C, Demirbas A, Acevedo RR, Grinyó J, Frei U, Vanrenterghem Y, Daloze P, Halloran P (2009) Calcineurin inhibitor minimization in the symphony study: observational results 3 years after transplantation. Am J Transplant 9(8):1876–1885
Euvrard S, Kanitakis J, Claudy A (2003) Skin cancers after organ transplantation. N Engl J Med 348(17):1681–1691
French AE, Soldin SJ, Soldin OP, Koren G (2003) Milk transfer and neonatal safety of tacrolimus. Ann Pharmacother 37(6):815–818
González-Vílchez F, Lambert JL, Rangel D, Almenar L, de la Fuente JL, Palomo J, Díaz Molina B, Lage E, Sánchez Lázaro I, Vázquez de Prada JA (2018) Efficacy and safety of de novo and early use of extended-release tacrolimus in heart transplantation. Rev Esp Cardiol (Engl Ed) 71(1):18–25
Guan P, Lu Y, Qi J, Niu M, Lian R, Hu F, Wu W (2011) Enhanced oral bioavailability of cyclosporineA by liposomes containing a bile salt. Int J Nanomedicine 6:965–674
Guo LQ, Fukuda K, Ohta T, Yamazoe Y (2000) Role of furanocoumarin derivatives on grapefruit juice-mediated inhibition of human CYP3A activity. Drug Metab Dispos 28(7):766–771
Hatanaka H, Iwami M, Kino T, Goto T, Okuhara M (1988) FR-900520 and FR-900523, novel immunosuppressants isolated from a Streptomyces. I. Taxonomy of the producing strain. J Antibiot 41(11):1586–1591
Heisel O, Heisel R, Balshaw R, Keown P (2004) New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. Am J Transplant 4(4):583–595
Hoorn EJ, Walsh SB, McCormick JA, Zietse R, Unwin RJ, Ellison DH (2012) Pathogenesis of calcineurin inhibitor-induced hypertension. J Nephrol 25(3):269–275
Imko-Walczuk B, Piesiaków ML, Trzonkowski P, Pikuła M, Dębska-Ślizień A, Rutkowski B (2016) Associations of selected cytokines levels in organ transplant recipients without and with malignant skin neoplasms. Transplant Proc 48(5):1654–1659
Kino T, Hatanaka H, Hashimoto M, Nishiyama M, Goto T, Okuhara M, Kohsaka M, Aoki H, Imanaka H (1987) FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. J Antibiot 40(9):1249–1255
Kwiek B, Peng WM, Allam JP, Langner A, Bieber T, Novak N (2008) Tacrolimus and TGF-beta act synergistically on the generation of Langerhans cells. J Allergy Clin Immunol 122(1):126–132
Levy G, Thervet E, Lake J, Uchida K, Consensus on Neoral C(2): Expert Review in Transplantation (CONCERT) Group (2002) Patient management by Neoral C(2) monitoring: an international consensus statement. Transplantation 73(9 Suppl):S12–S18
Liptak P, Ivanyi B (2006) Primer: histopathology of calcineurin-inhibitor toxicity in renal allografts. Nat Clin Pract Nephrol 2(7):398–404
Mancinelli LM, Frassetto L, Floren LC, Dressler D, Carrier S, Bekersky I, Benet LZ, Christians U (2001) The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups. Clin Pharmacol Ther 69(1):24–31
Matsuda S, Koyasu S (2000) Mechanisms of action of cyclosporine. Immunopharmacology 47(2–3):119–125
Matsuda S, Koyasu S (2003) Regulation of MAPK signaling pathways through immunophilin-ligand complex. Curr Top Med Chem 3(12):1358–1367
McAlister VC, Haddad E, Renouf E, Malthaner RA, Kjaer MS, Gluud LL (2006) Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: a meta-analysis. Am J Transplant 6(7):1578–1585
Oetting WS, Schladt DP, Guan W et al (2016) Genomewide association study of tacrolimus concentrations in African American kidney transplant recipients identifies multiple CYP3A5 alleles. Am J Transplant 16:574
Oto T, Okazaki M, Takata K, Egi M, Yamane M, Toyooka S, Sano Y, Snell GI, Goto K, Miyoshi S (2010) Calcineurin inhibitor-related cholestasis complicating lung transplantation. Ann Thorac Surg 89(5):1664–1665
Pennington CA, Park JM (2015) Sublingual tacrolimus as an alternative to oral administration for solid organ transplant recipients. Am J Health Syst Pharm 72:277
Puschett JB, Greenberg A, Holley J et al (1990) The spectrum of ciclosporin nephrotoxicity. Am J Nephrol 10:296–309
Rosenberg PB, Vriesendorp AE, Drazner MH et al (2005) Induction therapy with basiliximab allows delayed initiation of cyclosporine and preserves renal function after cardiac transplantation. J Heart Lung Transplant 24:1327
Senzolo M, Ferronato C, Burra P (2009) Neurologic complications after solid organ transplantation. Transpl Int 22(3):269–278
Steeves M, Abdallah HY, Venkataramanan R, Burckart GJ, Ptachcinski RJ, Abu-Elmagd K, Jain AK, Fung F, Todo S, Starzl TE (1991) In-vitro interaction of a novel immunosuppressant, FK 506, and antacids. J Pharm Pharmacol 43(8):574–577
Stojanova J, Caillard S, Rousseau A, Marquet P (2011) Post-transplant lymphoproliferative disease (PTLD): pharmacological, virological and other determinants. Pharmacol Res 63(1):1–7
Thiébaud D, Krieg MA, Gillard-Berguer D, Jacquet AF, Goy JJ, Burckhardt P (1996) Cyclosporine induces high bone turnover and may contribute to bone loss after heart transplantation. Eur J Clin Investig 26(7):549–555
Vakil K, Taimeh Z, Sharma A et al (2014) Incidence, predictors, and temporal trends of sudden cardiac death after heart transplantation. Heart Rhythm 11:1684–1690
Wuederrecht G, Lam E, Hung S et al (1993) The mechanism of action of FK-506 and cyclosporin a. Ann N Y Acad Sci 696:9
Yamamoto S, Kato R (1994) Hair growth-stimulating effects of cyclosporin A and FK506, potent immunosuppressants. J Dermatol Sci 7(Suppl):S47–S54
Author information
Authors and Affiliations
Corresponding authors
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply
About this chapter
Cite this chapter
Engwenyu, L.R., Anderson, A.S. (2021). A Comprehensive Review of Calcineurin Inhibitors Used for Immunosuppression in Cardiac Transplantation. In: Eisen, H.J. (eds) Pharmacology of Immunosuppression. Handbook of Experimental Pharmacology, vol 272. Springer, Cham. https://doi.org/10.1007/164_2021_549
Download citation
DOI: https://doi.org/10.1007/164_2021_549
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-05117-3
Online ISBN: 978-3-031-05118-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)